Biotricity Restates Equity, Reclassifies Preferred Stock
Ticker: BTCY · Form: 10-K/A · Filed: Jul 18, 2025 · CIK: 1630113
Sentiment: bearish
Topics: 10-K/A, Equity Restatement, Preferred Stock, Mezzanine Equity, Financial Reporting, Medical Devices, SEC Filing
Related Tickers: BTCY
TL;DR
**BTCY's equity restatement is a red flag, signaling potential balance sheet instability and warranting a cautious approach.**
AI Summary
BIOTRICITY INC.'s 10-K/A filing for the fiscal year ended March 31, 2025, primarily amends its previously filed 10-K, focusing on restatements related to equity and mezzanine financing. The filing indicates adjustments to the classification of Series B Convertible Redeemable Preferred Stock, which was reclassified from permanent equity to mezzanine equity. This reclassification impacts the company's balance sheet presentation for both March 31, 2025, and March 31, 2024. While specific revenue and net income figures are not detailed in the provided excerpt, the amendment highlights a critical change in the accounting treatment of its preferred stock, suggesting potential implications for its capital structure and financial health. The company's strategic outlook remains centered on its medical device and apparatus business, operating under SIC code 3841. The restatement underscores the importance of accurate financial reporting, particularly concerning complex financial instruments like convertible preferred stock, which can affect investor perception and valuation.
Why It Matters
This 10-K/A filing matters because it corrects the classification of BIOTRICITY's Series B Convertible Redeemable Preferred Stock, moving it from permanent equity to mezzanine equity. This reclassification can significantly alter how investors perceive the company's financial stability and leverage, as mezzanine equity often carries characteristics of both debt and equity. For employees and customers, while not directly impacting daily operations, it signals a need for precise financial governance. Competitively, accurate financial reporting is crucial for maintaining investor confidence, especially in the medical instruments sector where capital raises are frequent.
Risk Assessment
Risk Level: medium — The risk level is medium because the reclassification of Series B Convertible Redeemable Preferred Stock from permanent equity to mezzanine equity indicates a material accounting adjustment. While not necessarily a sign of fraud, such restatements can erode investor confidence and suggest complexities in the company's financial reporting, as seen in the adjustments for both March 31, 2025, and March 31, 2024.
Analyst Insight
Investors should scrutinize the full 10-K/A to understand the precise reasons for the reclassification and its impact on BIOTRICITY's overall financial health. A deeper dive into the terms of the Series B Preferred Stock is warranted to assess its debt-like features and potential dilution risks.
Key Numbers
- 2025-03-31 — Fiscal Year End (Period of report for the 10-K/A)
- 2025-07-18 — Filing Date (Date the 10-K/A was filed)
- 001-40761 — SEC File Number (BIOTRICITY's SEC file number)
- 3841 — SIC Code (Standard Industrial Classification for Surgical & Medical Instruments & Apparatus)
Key Players & Entities
- BIOTRICITY INC. (company) — filer of the 10-K/A
- SEC (regulator) — recipient of the 10-K/A filing
- Series B Convertible Redeemable Preferred Stock (other) — financial instrument reclassified
- Redwood City (other) — BIOTRICITY's business city
- Nevada (other) — state of incorporation for BIOTRICITY
- METASOLUTIONS, INC. (company) — BIOTRICITY's former company name
FAQ
What is the primary purpose of BIOTRICITY INC.'s 10-K/A filing?
The primary purpose of BIOTRICITY INC.'s 10-K/A filing is to amend its previously filed 10-K, specifically to restate the classification of its Series B Convertible Redeemable Preferred Stock from permanent equity to mezzanine equity for the fiscal years ended March 31, 2025, and March 31, 2024.
How does the reclassification of preferred stock impact BIOTRICITY's balance sheet?
The reclassification of Series B Convertible Redeemable Preferred Stock to mezzanine equity impacts BIOTRICITY's balance sheet by moving this instrument out of permanent equity, which can alter key financial ratios and the perceived capital structure. This change affects the presentation of equity for both March 31, 2025, and March 31, 2024.
What is the fiscal year-end for BIOTRICITY INC. as per this filing?
The fiscal year-end for BIOTRICITY INC. as per this 10-K/A filing is March 31, 2025, with comparative data also adjusted for March 31, 2024.
When was BIOTRICITY INC.'s 10-K/A filed with the SEC?
BIOTRICITY INC.'s 10-K/A was filed with the SEC on July 18, 2025, with a conformed period of report ending March 31, 2025.
What industry does BIOTRICITY INC. operate in, according to its SIC code?
According to its Standard Industrial Classification (SIC) code 3841, BIOTRICITY INC. operates in the Surgical & Medical Instruments & Apparatus industry.
What was BIOTRICITY INC.'s former company name?
BIOTRICITY INC.'s former company name was METASOLUTIONS, INC., with the name change occurring on January 7, 2015.
Why is a restatement of financial statements considered significant for investors?
A restatement of financial statements, such as the one by BIOTRICITY INC., is significant for investors because it indicates that previously reported financial information was incorrect. This can lead to a loss of investor confidence and may signal underlying issues with internal controls or accounting practices, potentially impacting stock valuation.
Where is BIOTRICITY INC.'s business located?
BIOTRICITY INC.'s business address is 203 Redwood Parkway, Suite 600, Redwood City, California 94065.
What is mezzanine equity and why is it different from permanent equity?
Mezzanine equity is a hybrid financing instrument that has characteristics of both debt and equity, often with a redemption feature or conversion rights. It differs from permanent equity because it typically has a finite life or specific conditions under which it must be repaid or converted, making it a more temporary form of capital than common stock.
What should investors do after reviewing BIOTRICITY's 10-K/A?
After reviewing BIOTRICITY's 10-K/A, investors should conduct further due diligence to understand the specific terms of the Series B Convertible Redeemable Preferred Stock, assess the impact of the reclassification on the company's debt-to-equity ratio, and evaluate any potential future dilution or redemption obligations.
Industry Context
BIOTRICITY INC. operates within the Surgical & Medical Instruments & Apparatus industry (SIC 3841). This sector is characterized by innovation in diagnostic and monitoring devices, driven by advancements in healthcare technology and an increasing demand for remote patient monitoring solutions. The competitive landscape includes established players and emerging companies focused on specialized medical technologies.
Regulatory Implications
The reclassification of preferred stock highlights the importance of accurate financial reporting and adherence to accounting standards (GAAP). Misclassification can lead to scrutiny from regulatory bodies like the SEC and may impact investor confidence. Companies must ensure complex financial instruments are correctly categorized to reflect their true financial position.
What Investors Should Do
- Review the specific details of the Series B Convertible Redeemable Preferred Stock terms.
- Analyze the pro forma balance sheets for March 31, 2025, and March 31, 2024.
- Assess the company's overall capital structure post-reclassification.
Key Dates
- 2025-03-31: Fiscal Year End — This is the period for which the 10-K/A filing reports, indicating the end of the company's fiscal year.
- 2025-07-18: Filing Date of 10-K/A — This is the date the amended annual report was officially filed with the SEC, providing updated financial information.
- 2024-03-31: Previous Fiscal Year End — This date represents the prior year-end balance sheet figures, against which the current year's restatements are compared.
- 2023-03-31: Prior Year Fiscal Year End — This date represents the balance sheet figures from two years prior, providing historical context for the equity reclassifications.
Glossary
- 10-K/A
- An amended annual report filed with the U.S. Securities and Exchange Commission (SEC) to correct or supplement information previously filed in a Form 10-K. (This filing specifically amends the previous 10-K, indicating a need for correction or addition of material information, particularly regarding equity.)
- Series B Convertible Redeemable Preferred Stock
- A class of preferred stock that has the option to be converted into common stock, can be redeemed (bought back) by the company, and has redemption features that may require it to be classified outside of permanent equity. (The reclassification of this stock from permanent equity to mezzanine equity is the primary focus of this amendment, impacting the company's capital structure.)
- Mezzanine Equity
- A category of equity that falls between debt and common equity. It often includes securities with features of both, such as preferred stock with redemption rights, which are not considered permanent equity. (The reclassification of Series B Preferred Stock to this category signifies a change in how the company's capital is presented, potentially affecting leverage ratios and investor perception.)
- SIC Code 3841
- Standard Industrial Classification code for Surgical & Medical Instruments & Apparatus, indicating the company's primary business sector. (This code confirms BIOTRICITY INC.'s focus on the medical device industry, providing context for its operations and market.)
Year-Over-Year Comparison
This 10-K/A filing is an amendment to the previously filed 10-K for the fiscal year ended March 31, 2025. The primary change involves the reclassification of Series B Convertible Redeemable Preferred Stock from permanent equity to mezzanine equity for both the March 31, 2025, and March 31, 2024, balance sheets. This restatement impacts the presentation of the company's capital structure but does not appear to alter the underlying business operations or reported revenue and net income figures from the original filing, based on the provided excerpt.
Filing Details
This Form 10-K/A (Form 10-K/A) was filed with the SEC on July 18, 2025 regarding BIOTRICITY INC. (BTCY).